Multidrug Resistance Protein 1 inhibitors to sensitise cancers to chemotherapy [ 2018 - 2020 ]

Research Grant

Researchers: Prof Michelle Haber (Principal investigator) ,  A/Pr Ian Street ,  Dr Jamie Fletcher ,  Prof Benjamin Solomon ,  Prof Murray Norris

Brief description Multidrug resistance protein 1 (MRP1) is often present at high levels in cancer cells, where it pumps chemotherapy drugs back out, causing drug resistance. Inhibitors that block MRP1 would increase the effectiveness of chemotherapy. We have developed MRP1 inhibitors with promising activity in cancer cells and mouse tumours and will now develop these inhibitors for clinical application and commercialisation.

Funding Amount $AUD 851,928.33

Funding Scheme Development Grants

Notes Development Grant